390 related articles for article (PubMed ID: 15156185)
1. Point mutations in the RUNX1/AML1 gene: another actor in RUNX leukemia.
Osato M
Oncogene; 2004 May; 23(24):4284-96. PubMed ID: 15156185
[TBL] [Abstract][Full Text] [Related]
2. AML1/RUNX1 mutations are infrequent, but related to AML-M0, acquired trisomy 21, and leukemic transformation in pediatric hematologic malignancies.
Taketani T; Taki T; Takita J; Tsuchida M; Hanada R; Hongo T; Kaneko T; Manabe A; Ida K; Hayashi Y
Genes Chromosomes Cancer; 2003 Sep; 38(1):1-7. PubMed ID: 12874780
[TBL] [Abstract][Full Text] [Related]
3. Core binding factor genes and human leukemia.
Hart SM; Foroni L
Haematologica; 2002 Dec; 87(12):1307-23. PubMed ID: 12495904
[TBL] [Abstract][Full Text] [Related]
4. Familial platelet disorder with propensity to acute myelogenous leukemia: genetic heterogeneity and progression to leukemia via acquisition of clonal chromosome anomalies.
Minelli A; Maserati E; Rossi G; Bernardo ME; De Stefano P; Cecchini MP; Valli R; Albano V; Pierani P; Leszl A; Sainati L; Lo Curto F; Danesino C; Locatelli F; Pasquali F
Genes Chromosomes Cancer; 2004 Jul; 40(3):165-71. PubMed ID: 15138996
[TBL] [Abstract][Full Text] [Related]
5. Point mutations of the RUNx1/AML1 gene in sporadic and familial myeloid leukemias.
Osato M; Yanagida M; Shigesada K; Ito Y
Int J Hematol; 2001 Oct; 74(3):245-51. PubMed ID: 11721958
[TBL] [Abstract][Full Text] [Related]
6. Identification of RUNX1/AML1 as a classical tumor suppressor gene.
Silva FP; Morolli B; Storlazzi CT; Anelli L; Wessels H; Bezrookove V; Kluin-Nelemans HC; Giphart-Gassler M
Oncogene; 2003 Jan; 22(4):538-47. PubMed ID: 12555067
[TBL] [Abstract][Full Text] [Related]
7. Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations.
Harada Y; Harada H
J Cell Physiol; 2009 Jul; 220(1):16-20. PubMed ID: 19334039
[TBL] [Abstract][Full Text] [Related]
8. Somatic point mutations in RUNX1/CBFA2/AML1 are common in high-risk myelodysplastic syndrome, but not in myelofibrosis with myeloid metaplasia.
Steensma DP; Gibbons RJ; Mesa RA; Tefferi A; Higgs DR
Eur J Haematol; 2005 Jan; 74(1):47-53. PubMed ID: 15613106
[TBL] [Abstract][Full Text] [Related]
9. Novel loss-of-function mutations of the haematopoiesis-related transcription factor, acute myeloid leukaemia 1/runt-related transcription factor 1, detected in acute myeloblastic leukaemia and myelodysplastic syndrome.
Nakao M; Horiike S; Fukushima-Nakase Y; Nishimura M; Fujita Y; Taniwaki M; Okuda T
Br J Haematol; 2004 Jun; 125(6):709-19. PubMed ID: 15180860
[TBL] [Abstract][Full Text] [Related]
10. Oncogenic potential of the RUNX gene family: 'overview'.
Ito Y
Oncogene; 2004 May; 23(24):4198-208. PubMed ID: 15156173
[TBL] [Abstract][Full Text] [Related]
11. Molecular mechanisms that produce secondary MDS/AML by RUNX1/AML1 point mutations.
Harada Y; Harada H
J Cell Biochem; 2011 Feb; 112(2):425-32. PubMed ID: 21268063
[TBL] [Abstract][Full Text] [Related]
12. Functional mutagenesis of AML1/RUNX1 and PEBP2 beta/CBF beta define distinct, non-overlapping sites for DNA recognition and heterodimerization by the Runt domain.
Nagata T; Werner MH
J Mol Biol; 2001 Apr; 308(2):191-203. PubMed ID: 11327761
[TBL] [Abstract][Full Text] [Related]
13. New mechanisms of AML1 gene alteration in hematological malignancies.
Roumier C; Fenaux P; Lafage M; Imbert M; Eclache V; Preudhomme C
Leukemia; 2003 Jan; 17(1):9-16. PubMed ID: 12529654
[TBL] [Abstract][Full Text] [Related]
14. Dual mutations in the AML1 and FLT3 genes are associated with leukemogenesis in acute myeloblastic leukemia of the M0 subtype.
Matsuno N; Osato M; Yamashita N; Yanagida M; Nanri T; Fukushima T; Motoji T; Kusumoto S; Towatari M; Suzuki R; Naoe T; Nishii K; Shigesada K; Ohno R; Mitsuya H; Ito Y; Asou N
Leukemia; 2003 Dec; 17(12):2492-9. PubMed ID: 14562119
[TBL] [Abstract][Full Text] [Related]
15. Increased dosage of Runx1/AML1 acts as a positive modulator of myeloid leukemogenesis in BXH2 mice.
Yanagida M; Osato M; Yamashita N; Liqun H; Jacob B; Wu F; Cao X; Nakamura T; Yokomizo T; Takahashi S; Yamamoto M; Shigesada K; Ito Y
Oncogene; 2005 Jun; 24(28):4477-85. PubMed ID: 15856017
[TBL] [Abstract][Full Text] [Related]
16. In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: implications for mechanisms of pathogenesis.
Michaud J; Wu F; Osato M; Cottles GM; Yanagida M; Asou N; Shigesada K; Ito Y; Benson KF; Raskind WH; Rossier C; Antonarakis SE; Israels S; McNicol A; Weiss H; Horwitz M; Scott HS
Blood; 2002 Feb; 99(4):1364-72. PubMed ID: 11830488
[TBL] [Abstract][Full Text] [Related]
17. The 8;21 translocation in leukemogenesis.
Peterson LF; Zhang DE
Oncogene; 2004 May; 23(24):4255-62. PubMed ID: 15156181
[TBL] [Abstract][Full Text] [Related]
18. Role of RUNX family members in transcriptional repression and gene silencing.
Durst KL; Hiebert SW
Oncogene; 2004 May; 23(24):4220-4. PubMed ID: 15156176
[TBL] [Abstract][Full Text] [Related]
19. Proviral insertion indicates a dominant oncogenic role for Runx1/AML-1 in T-cell lymphoma.
Wotton S; Stewart M; Blyth K; Vaillant F; Kilbey A; Neil JC; Cameron ER
Cancer Res; 2002 Dec; 62(24):7181-5. PubMed ID: 12499254
[TBL] [Abstract][Full Text] [Related]
20. Targeting the oligomerization domain of ETO interferes with RUNX1/ETO oncogenic activity in t(8;21)-positive leukemic cells.
Wichmann C; Chen L; Heinrich M; Baus D; Pfitzner E; Zörnig M; Ottmann OG; Grez M
Cancer Res; 2007 Mar; 67(5):2280-9. PubMed ID: 17332359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]